ClinicalTrials.gg
CompletedNCT04313153Updated May 22, 2025Results posted

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

A Phase 3 interventional study of Vadadustat and Darbepoetin alfa in Anemia, sponsored by Akebia Therapeutics. Completed at 59 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-22.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
8th of 27
319 · median 60
Started
2020
the only one that year
Phase 3
14 of 27
none open now
Registered
22nd of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 8th largest by enrollment, is the only one that started in 2020, is one of 14 in phase 3, and was the 22nd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This trial will be conducted to demonstrate the efficacy and safety of vadadustat compared to darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants after conversion from current erythropoiesis-stimulating agent (ESA) therapy.

Read the detailed description

This study consists of three periods:

  1. Screening Period
  2. Conversion and Maintenance Treatment Period
  3. Safety Follow-up Period

Individual participants will participate in total trial duration of approximately 64 weeks.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • vadadustat
  • hemodialysis
  • erythropoiesis-stimulating agents
  • darbepoetin alfa
  • CKD
  • Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Receiving chronic, outpatient three times weekly (TIW) in-center hemodialysis for end-stage renal disease for at least 12 weeks prior to Screening
  • Hemodialysis adequacy as indicated by single-pool Kt/Vurea ≥ 1.2 using the most recent historical measurement within 8 weeks prior to or during Screening
  • Use of any approved erythropoiesis-stimulating agents (ESAs) for at least the 8 weeks prior to Screening Visit 2
  • Two (Hb) values, at least 4 days apart, measured by the central laboratory during Screening within the following prespecified ranges:

    1. Hb values between 8.0 and 11.0 grams per deciliter (g/dL) (inclusive) in the United States;
    2. Hb values between 9.0 and 12.0 g/dL (inclusive) in Europe
  • Serum ferritin ≥ 100 nanograms per milliliter (ng/mL) and transferrin saturation (TSAT) ≥ 20% during Screening
  • Folate and vitamin B12 measurements ≥ lower limit of normal during Screening

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than chronic kidney disease (e.g., sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic , myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia)
  • Participants meeting cut-off of the following equivalent mean weekly doses calculated over 8 weeks prior to Screening Visit 2

    1. Methoxy polyethylene glycol-epoetin beta > 50 micrograms (µg)/week;
    2. Darbepoetin alfa > 100 µg/week;
    3. Epoetin analogues > 23000 International Units (IU)/week
  • Active bleeding or recent blood loss within 8 weeks prior to randomization
  • Red blood cell transfusion within 8 weeks prior to randomization
  • Current uncontrolled hypertension.
  • Acute coronary syndrome (hospitalization for unstable angina or myocardial infarction), surgical or percutaneous intervention for coronary, cerebrovascular or peripheral artery disease (aortic or lower extremity), surgical or percutaneous valvular replacement or repair, sustained ventricular tachycardia, hospitalization for heart failure (HF) or Class IV HF, or stroke within 12 weeks prior to or during Screening.
  • Known to vadadustat, darbepoetin alfa, or any of their
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
319 participants (actual)

Study arms

  • Experimental
    Vadadustat once daily (QD)

    Drug: Vadadustat

  • Experimental
    Vadadustat three times weekly (TIW)

    Drug: Vadadustat

  • Active comparator
    Darbepoetin alfa

    Drug: Darbepoetin alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)

    The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26, regardless of intercurrent events. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.

    Time frame: Baseline; Weeks 20 to 26

Secondary outcomes

  1. Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)

    The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52, regardless of intercurrent events. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.

    Time frame: Baseline; Weeks 46 to 52

07

Results

Posted May 22, 2025
Limitations and caveats
Per the protocol, data was collected by the arm to which participants were randomized and not by dose received in vadadustat QD or vadadustat TIW arms.

Participant flow

This was a randomized, open-label, active-controlled study of vadadustat versus darbepoetin alfa for the maintenance treatment of anemia in hemodialysis participants, after conversion from erythropoiesis-stimulating agent (ESA therapy).

Participant flow — Overall Study
MilestoneVadadustat QDVadadustat TIWDarbepoetin Alfa
Started105106108
Completed545067
Not completed515641
Withdrew: Adverse event (includes death)141910
Withdrew: Physician decision421
Withdrew: Withdrawal by subject762
Withdrew: Lack of efficacy330
Withdrew: Lost to follow-up102
Withdrew: Receipt of a solid organ, hematopoietic stem cell, or bone marrow transplantation023
Withdrew: Meeting criteria for trial medication stopping rules162019
Withdrew: Change in dialysis modality012
Withdrew: Permanent change in frequency of in-center hemodialysis from tiw100
Withdrew: Other532

Outcome measures

PrimaryChange From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)

The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the PEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 20 through 26, regardless of intercurrent events. Analysis was conducted using an analysis of covariance (ANCOVA) model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as PEP value minus the Baseline value.

Time frame:
Baseline; Weeks 20 to 26
Reported as:
Least squares mean · Grams per deciliter (g/dL)
Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)
Grams per deciliter (g/dL)Vadadustat QDVadadustat TIWDarbepoetin Alfa
Change From Baseline in Hb to the Average Over the Primary Evaluation Period (PEP) (Weeks 20 to 26)0.07 ± 0.12-0.19 ± 0.120.34 ± 0.12
SecondaryChange From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)

The Baseline Hb was defined as the average of the last 2 central laboratory Hb values taken on or prior to the first dose date. The average for the SEP was calculated as the average of all Hb measurements from the central laboratory within the three visit windows during Weeks 46 through 52, regardless of intercurrent events. Analysis was conducted using an ANCOVA model with multiple imputation for missing data with randomization stratification factors and Baseline Hb as covariates. Change from Baseline was calculated as SEP value minus the Baseline value.

Time frame:
Baseline; Weeks 46 to 52
Reported as:
Least squares mean · g/dL
Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)
g/dLVadadustat QDVadadustat TIWDarbepoetin Alfa
Change From Baseline in Hb to the Average Over the Secondary Evaluation Period (SEP) (Weeks 46 to 52)0.04 ± 0.150.03 ± 0.150.44 ± 0.15

Adverse events

Collected over From first dose of study drug (Day 1) up to Week 56 (from first dose of study drug to last dose + 4 weeks of follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vadadustat QD12/105 (11.4%)47/105 (44.8%)46/105 (43.8%)
Vadadustat TIW9/104 (8.7%)47/104 (45.2%)49/104 (47.1%)
Darbepoetin Alfa7/108 (6.5%)47/108 (43.5%)46/108 (42.6%)
Most frequent serious events
Showing 10 of 155
Most frequent serious events
EventVadadustat QDVadadustat TIWDarbepoetin Alfa
COVID-19 pneumoniaInfections and infestations7/1058/1044/108
Acute myocardial infarctionCardiac disorders2/1056/1040/108
AnaemiaBlood and lymphatic system disorders3/1055/1045/108
HypervolaemiaMetabolism and nutrition disorders2/1054/1044/108
COVID-19Infections and infestations2/1052/1044/108
Myocardial infarctionCardiac disorders0/1053/1041/108
Gastrointestinal haemorrhageGastrointestinal disorders0/1053/1040/108
PneumoniaInfections and infestations2/1053/1041/108
SepsisInfections and infestations1/1053/1043/108
Non-cardiac chest painGeneral disorders3/1051/1040/108
Most frequent other events
Showing 10 of 12
Most frequent other events
EventVadadustat QDVadadustat TIWDarbepoetin Alfa
DiarrhoeaGastrointestinal disorders14/10515/1046/108
NauseaGastrointestinal disorders12/1056/1046/108
COVID-19Infections and infestations12/10511/10410/108
HypertensionVascular disorders6/10511/10410/108
VomitingGastrointestinal disorders10/1054/1046/108
FallInjury, poisoning and procedural complications10/1056/1045/108
HyperkalaemiaMetabolism and nutrition disorders4/1055/1049/108
Abdominal painGastrointestinal disorders4/1054/1048/108
AnaemiaBlood and lymphatic system disorders5/1057/1047/108
Back painMusculoskeletal and connective tissue disorders2/1056/1042/108

Baseline characteristics

Randomized Population is defined as all participants randomized.

Age, Continuous
Age, Continuous(years)Vadadustat QDVadadustat TIWDarbepoetin AlfaTotal
Mean60.9 ± 13.461.2 ± 12.560.8 ± 12.861.0 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Vadadustat QDVadadustat TIWDarbepoetin AlfaTotal
Female474643136
Male586065183
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vadadustat QDVadadustat TIWDarbepoetin AlfaTotal
Hispanic or Latino23362685
Not Hispanic or Latino827082234
Unknown or Not Reported0000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vadadustat QDVadadustat TIWDarbepoetin AlfaTotal
American Indian or Alaska Native1203
Asian4138
Black Or African American31303394
Native Hawaiian or Other Pacific Islander0213
White686771206
Not Reported1304
Reported as Other0101
08

Study locations

59 sites
  • Research Site
    Chula Vista, California 91910, United States
  • Research Site
    Granada Hills, California 91344, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Lynwood, California 90262, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    Whittier, California 90603, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Middlebury, Connecticut 06762, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Tampa, Florida 33614, United States
  • Research Site
    Winter Park, Florida 32789, United States
  • Research Site
    Pontiac, Michigan 48341, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site
    Minneapolis, Minnesota 55404, United States
  • Research Site
    Brookhaven, Mississippi 39601, United States
  • Research Site
    Tupelo, Mississippi 38801, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Saint Louis, Missouri 63136, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Albuquerque, New Mexico 87109, United States
  • Research Site
    Durham, North Carolina 27704, United States
  • Research Site
    Kinston, North Carolina 28504, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    Orangeburg, South Carolina 29118, United States
  • Research Site
    Chattanooga, Tennessee 37404, United States
  • Research Site
    Knoxville, Tennessee 37920, United States
  • Research Site
    Knoxville, Tennessee 37923, United States
  • Research Site
    Austin, Texas 78751, United States
  • Research Site
    Austin, Texas 78758, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    McAllen, Texas 78503, United States
  • Research Site
    San Antonio, Texas 78204, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Hampton, Virginia 23666, United States
  • Research Site
    Mariánské Lázně, Czechia
  • Research Site
    Nový Jičín, Czechia
  • Research Site
    Plzen, Czechia
  • Research Site
    Praha 9, Czechia
  • Research Site
    Příbram, Czechia
  • Research Site
    Slaný, Czechia
  • Research Site
    Baja, Hungary
  • Research Site
    Debrecen, Hungary
  • Research Site
    Kaposvar, Hungary
  • Research Site
    Kecskemét, Hungary
  • Research Site
    Pécs, Hungary
  • Research Site
    Pavia, Italy
  • Research Site
    Vicenza, Italy
  • Research Site
    Biała Podlaska, Poland
  • Research Site
    Brodnica, Poland
  • Research Site
    Lodz, Poland
  • Research Site
    Pszczyna, Poland
  • Research Site
    Sochaczew, Poland
  • Research Site #2
    Barcelona, Spain
  • Research Site
    Valencia, Spain
09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Nov 2021, 17 months.

Results were first posted in May 2025, 3 years 5 months after primary completion. A results delay was requested in Nov 2022.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 17 months is below that.

Counting every sponsor, half of 150 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2020
First posted
Mar 18, 2020
StartActual
May 27, 2020
Primary completionActual
Nov 26, 2021
CompletionActual
Jun 22, 2022
Results delay requested
Nov 10, 2022
Results first posted
May 22, 2025
Last update
May 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04313153
Responsible party
Sponsor
First posted
Mar 18, 2020
Start date
May 27, 2020
Primary completion
Nov 26, 2021
Completion
Jun 22, 2022
Results posted
May 22, 2025
Last update
May 22, 2025

Study contacts

Chief Medical Officer
study director · Akebia Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion